Who
Nancy Miller-Rich
Director
Company insider
Files Form 4 as: Director, 4D Molecular Therapeutics; Director, Aldeyra Therapeutics; Director, Intercept Pharmaceuticals; Director, Kadmon Holdings.
In numbers
- Trades disclosed
- 49
- Buys
- 2
- Sells
- 0
- Bought
- $10K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 20 Jun 2018
- Last trade
- 17 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 18 Jun 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,318 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,318 at $0.00 | filing |
| 17 Jun 2025filed 20 Jun 2025 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,728 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,413 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,282 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,736 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —12,089 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —12,790 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —12,547 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —7,684 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —2,174 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —2,966 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticals | SEC FORM 4 Code U | $424K22,304 at $19.00 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticals | SEC FORM 4 Code D | $154K8,111 at $19.00 | filing |
News
No headline names them, or the companies they trade most, lately.